How do you anticipate rusfertide will be used in the management of polycythemia vera?
Do you think it will become first-line therapy? Is potential iron overload a concern with long-term use?
Bankar et al. VERIFY: A randomized controlled phase 3 study of the hepcidin mimetic rusfertide (PTG-300) in patients with polycythemia vera (PV). ASCO 2025
Community PollStarted
What concerns, if any, do you have with using rusfertide as 1L therapy in the management of polycythemia vera? (select all)
14 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Hematology · Johns Hopkins University
Answered on
Rusfertide, an injectable hepcidin mimetic (1), is another new arrow in the quiver of 21st-century therapies for controlling erythropoiesis without phlebotomy in polycythemia vera (PV), though likely to be replaced in the near future by gene silencing technology, which does not require as frequent d...
Join for free or sign in to see the full answer